Laboratory-based versus non-laboratory-based World Health Organization risk equations for assessment of

Azizallah Dehghan1, Ali Rayatinejad2, Rozhan Khezri3

  • 1Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.

Insights

The non-laboratory-based WHO cardiovascular risk model shows substantial agreement with its laboratory-based counterpart. This makes it a viable tool for risk assessment in resource-limited settings.

Area of Science:

  • Cardiology
  • Public Health
  • Epidemiology

Background:

  • The World Health Organization (WHO) provides cardiovascular disease risk prediction models.
  • These models exist in both laboratory-based and non-laboratory-based formats.
  • Accessibility to laboratory facilities can be a barrier in certain healthcare settings.

Purpose of the Study:

  • To evaluate the agreement between laboratory-based and non-laboratory-based WHO cardiovascular risk equations.
  • To assess the utility of the non-laboratory-based model for cardiovascular risk prediction.

Main Methods:

  • A cross-sectional study utilizing baseline data from 6796 individuals in the Fasa cohort.
  • Comparison of risk factors: laboratory model (age, sex, SBP, diabetes, smoking, total cholesterol) vs. non-laboratory model (age, sex, SBP, smoking, BMI).
  • Statistical analysis included Kappa coefficients for grouped risk agreement and Bland-Altman plots for score agreement.

Main Results:

  • Substantial agreement was found between the two models across the general population (kappa=0.68).
  • Agreement varied by age and sex, with generally substantial agreement, though moderate in older age groups.
  • The non-laboratory model demonstrated acceptable sensitivity (e.g., 100% for several subgroups at a 10% risk threshold) for identifying high-risk individuals.

Conclusions:

  • The non-laboratory-based WHO cardiovascular risk model demonstrates good agreement with the laboratory-based version.
  • The non-laboratory model offers acceptable sensitivity for practical risk assessment in resource-limited settings.
  • This model is suitable for screening programs where laboratory access is restricted.
Abstract

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
238
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
166
Odds Ratio01:09

Odds Ratio

The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
186
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
375
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
204